Selected article for: "cytokine response and disease severity"
Author: Maione, Francesco; Casillo, Gian Marco; Raucci, Federica; Salvatore, Cristian; Ambrosini, Giovanna; Costa, Luisa; Scarpa, Raffaele; Caso, Francesco; Bucci, Mariarosaria
Title: Interleukin-17A (IL-17A): a silent amplifier of COVID-19
  • Cord-id: 1tjzxb2r
  • Document date: 2021_7_29
    • ID: 1tjzxb2r
    Snippet: One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a
    Document: One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and local site: 1
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome patient and lung injury: 1, 2, 3, 4, 5, 6
    • acute inflammation and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute inflammation and adaptive innate immunity: 1, 2, 3, 4, 5, 6, 7
    • acute inflammation and low mortality: 1, 2, 3
    • acute inflammation and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute lung injury and adaptive innate immunity: 1, 2, 3, 4
    • acute lung injury and local site: 1
    • acute lung injury and low mortality: 1, 2, 3, 4, 5
    • acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury patient and lung injury: 1, 2, 3, 4, 5, 6
    • acute phase and adaptive innate immunity: 1, 2, 3
    • acute phase and low mortality: 1, 2, 3
    • acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25